CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism

Immunity

Volumn 11, Issue 4, 1999, Pages 483-493

  Shrikant, Protul ^a   Khoruts, Alexander ^a,b   Mescher, Matthew F ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 2;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CLONAL ANERGY; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

EID: 0033213599     PISSN: 10747613     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-7613(00)80123-5     Document Type: Article

References (46)

1. Bennett, S.R.M., Carbone, F.R., Karamalis, F., Flavell, R.A., Miller, J.F.A.P., and Heath, W.R. (1998). Help for cytotoxic T-cell responses is mediated by CD40 signaling. Nature 393, 478-480.
2. Boon, T., Cerottini, J.-C., Van den Eynde, B., Van der Bruggen, P., and Van Pel, A. (1994). Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12, 337-365.
3. Brossart, P., Goldrath, A.W., Butz, E.A., Martin, S., and Bevan, M.J. (1997). Virus mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL activity. J. Immunol. 158, 3270-3276.
4. + T cells. J. Exp. Med. 184, 863-871.
5. Chambers, C.A., Krummel, M.F., Boitel, B., Hurwitz, A., Sullivan, T.J., Fournier, S., Cassell, D., Brunner, M., and Allison, J.P. (1996). The role of CTLA-4 in the regulation and initiation of T-cell responses. Immunol. Rev. 153, 27-46.
6. + T cells. Eur. J. Immunol. 28, 3137-3143.
7. Chaux, P., Vantomme, V., Stroobant, V., Thielemans, K., Corthals, J., Luiten, R., Eggermont, A.M., Boon, T., and Van der Bruggen, P. (1999). Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J. Exp. Med. 189, 767-778.
8. D'Souza, S., Rimoldi, D., Lienard, D., Lejeune, F., Cerottini, J.C., and Romero, P. (1998). Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype. Int. J. Cancer 78, 699-706.
9. + T cells become non-responsive (anergic) following activation in the presence of costimulation. J. Immunol. 163, 102-110.
10. Dialynas, D., Quan, Z., Wall, K., Pierres, A., Quintans, J., Loken, M., Pierres, M., and Fitch, F. (1983). Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: Similarity of L3T4 to the human LEU-3/T4 molecule. J. Immunol. 131, 2445-2451.
11. Fenton, R., Taub, D., Kwak, L., Smith, M., and Longo, D. (1993). Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes. J. Natl. Cancer Inst. 85, 1294-1302.
12. Greenberg, P.D., Cheever, M.A., and Fefer, A. (1981). Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes. J. Exp. Med. 154, 952-963.
13. Halder, T., Pawelec, G., Kirkin, A.F., Zeuthen, J., Meyer, H.E., Kun, L., and Kalbacher, H. (1997). Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Cancer Res. 57, 3238-3244.
14. Hogquist, K., Jameson, S., Heath, W., Howard, J., Bevan, M., and Carbone, F. (1994). T cell receptor antagonist peptides induce positive selection. Cell 76, 17-27.
15. Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., and Levitsky, H. (1998). The central role of CD4(+) T cells in the antitumor immune response. J. Exp. Med. 188, 2357-2368.
16. Hurwitz, A.A., Yu, T.F.Y., Leach, D.R., and Allison, J.P. (1998). CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl. Acad. Sci. USA 95, 10067-10071.
17. Jantzer, P., and Schendel, D.J. (1998). Human renal cell carcinoma antigen-specific CTLs: Antigen-driven selection and long-term persistence in vivo. Cancer Res. 58, 3078-3086.
18. Keene, J.A., and Forman, J. (1982). Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J. Exp. Med. 155, 768-782.
19. Kwon, E.D., Hurwitz, A.A., Foster, B.A., Madias, C., Feldhaus, A.L., Greenberg, N.M., Burg, M.B., and Allison, J.P. (1997). Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc. Natl. Acad. Sci USA 94, 8099-8103.
20. Kyburz, D., Aichele, P., Speiser, D., Hengartner, H., Zinkernagel, R., and Pircher, H. (1993). T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptides. Eur. J. Immunol. 23, 1956-1962.
21. Leach, D.R., Krummel, M.F., and Allison, J.P. (1996). Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734-1736.
22. Lee, P.P., Yee, C., Savage, P.A., Fong, L., Brockstedt, D., Weber, J.S., Johnson, D., Swetter, S., Thompson, J., Greenberg, P.D., et al. (1999). Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5, 677-685.
23. Manici, S., Sturniolo, T., Imro, M.A., Hammer, J., Sinigaglia, F., Noppen, C., Spagnoli, G., Mazzi, B., Bellone, M., Dellabona, P., et al. (1999). Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J. Exp. Med. 189, 871-876.
24. + cytotoxic T-cell responses during chronic viral infection. J. Virol. 68, 8056-8063.
25. McCoy, K.D., Hermans, I.F., Henry Fraser, J., Le Gros, G., and Ronchese, F. (1999). Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) can regulate dendritic cell-induced activation and cytotoxicity of CD8(+) T cells independently of CD4(+) T cell help. J. Exp. Med. 189, 1157-1162.
26. + T-cell responses and prolongs survival of thymoma-bearing mice. Cancer Res. 54, 4155-4161.
27. Mokyr, M.B., Kalinichenko, T., Gorelik, L., and Bluestone, J.A. (1998). Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. Cancer Res. 58, 5301-5304.
28. Moore, M., Carbone, F., and Bevan, M. (1988). Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54, 777-785.
29. + cytotoxic T lymphocyte responses. J. Immunol. 148, 2357-2362.
30. Ossendorp, F., Mengede, E., Camps, M., Filius, R., and Melief, C.J.M. (1998). Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibilty complex class II negative tumors. J. Exp. Med. 187, 693-702.
31. + T cell: Receptor-dependent cytolysis in the absence of interleukin-2 production. Science 251, 1228-1231.
32. + T cell responses in antitumor immunity. Curr. Opin. Immunol. 10, 588-594.
33. Perez, V.L., Van Parijs, L., Biuckians, A., Zheng, X.X., Strom, T.B., and Abbas, A.K. (1997). Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 6, 411-417.
34. Pieper, R., Christian, R.E., Gonzales, M.I., Nishimura, M.I., Gupta, G., Settlage, R.E., Shabanowitz, J., Rosenberg, S.A., Hunt, D.F., and Topalian, S.L. (1999). Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells. J. Exp. Med. 189, 757-766.
35. Porgador, A., Snyder, D., and Gilboa, E. (1996). Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol. 156, 2918-2926.
36. + T-helper and a T-killer cell. Nature 393, 474-478.
37. Schoenberger, S.P., Toes, R.E.M., Van der Voort, E.I.H., Offringa, R., and Melief, C.J.M. (1998). T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393, 480-483.
38. Shimonkevitz, R., Colon, S., Kappler, J.W., Marrack, P., and Grey, H.M. (1984). Antigen recognition by H-2-restricted T cells. II. A tryptic ovalbumin peptide that substitutes for processed antigen. J. Immunol. 133, 2067-2074.
39. + T cells: Efficacy is limited by migration away from the site and induction of nonresponsiveness. J. Immunol. 162, 2858-2866.
40. Staveley-O'carroll, K., Sotomayor, E., Montgomery, J., Borrello, I., Hwang, L., Fein, S., Pardoll, D., and Levitsky, H. (1998). Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95, 1178-1183.
41. Stevenson, P.G., Belz, G.T., Altman, J.D., and Doherty, P.C. (1998). Virus-specific CD8(+) T cell numbers are maintained during gamma-herpesvirus reactivation in CD4-deficient mice. Proc. Natl. Acad. Sci. USA 95, 15565-15570.
42. + T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J. Exp. Med. 183, 1965-1971.
43. Walunas, T.L., Lenschow, D.J., Bakker, C.Y., Linsley, P.S., Freeman, G.J., Green, J.M., Thompson, C.B., and Bluestone, J.A. (1994). CTLA-4 can function as a negative regulator of T cell activation. Immunity 1, 405-413.
44. Yang, Y.F., Zou, J.P., Mu, J., Wijesuriya, R., Ono, S., Walunas, T., Bluestone, J., Fujiwara, H., and Hamaoka, T. (1997). Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: The effect is manifested only at the restricted tumor-bearing stages. Cancer Res. 57, 4036-4041.
45. Zajac, A.J., Blattman, J.N., Murali-Krishna, K., Sourdive, D.J.D., Suresh, M., Altman, J.D., and Ahmed, R. (1999). Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188, 2205-2213.
46. Zhou, F., Rouse, B.T., and Huang, L. (1992). Prolonged survival of thymoma-bearing mice after vaccination with a soluble protein antigen entrapped in liposomes: A model study. Cancer Res. 52, 6287-6291.